Cancer variant knowledgebases and molecular tumour boards
Curated databases that say what each mutation means for treatment, and the expert meetings that use them to decide on therapy.
OncoKB (MSK; FDA-recognised), CIViC (WashU; open, crowd-curated), My Cancer Genome (Vanderbilt), JAX-CKB, COSMIC (Sanger), ClinVar, and cBioPortal supply the evidence layer for precision oncology; molecular tumour boards (institutional, national such as the UK's Genomic MDTs, and virtual services from Roche NAVIFY, Syapse, and Tempus) apply it to patients. Studies show actionable findings in 30-50% of sequenced patients but treatment uptake of only 10-25%, pointing to access and evidence gaps.
How it works
Expert curation of gene-variant-disease-drug evidence into levels (e.g. OncoKB 1-4, R1-R2), exposed by API for lab reporting and decision support.
- Open, citable evidence
- Regulatory recognition (OncoKB)
- Curation lag and disagreement between sources
- Sparse evidence for rare variants
- Tumour-board capacity
Latest papers
topQuery for this technology: (TITLE:"Cancer variant knowledgebases and molecular tumour boards" OR ABSTRACT:"Cancer variant knowledgebases and molecular tumour boards") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cancer variant knowledgebases and molecular tumour boards, not a curated reading list.